Biopharma | Ophthalmology Innovation Source

Ocular Therapeutix

The company is evaluating sustained-release injectable anti-VEGF drug depots along with use of its proprietary hydrogel platform technology for anterior segment disorders (specifically pain and inflammation). Ocular Therapeutix’s OTX drug-eluting punctal plug is a non-invasive procedure that will eliminate drops (and the potential non-compliance). During the past year, the company completed two of three planned…

Ophthalmology Innovation Summit Gives Nod to Successful Public Start-ups

Largest ever gathering will showcase recent IPO Companies, early stage companies and speech by Allergan’s CEO LAS VEGAS, NV (PRWEB) NOVEMBER 12, 2015 The seventh annual Ophthalmology Innovation Summit today (OIS) will draw more than 900 clinicians, investors and executives upon the Planet Hollywood Hotel in Las Vegas for a glimpse of the world’s most…

Biggest OIS Ever Set to Deliver News & Insights

The maturation and advance of the ophthalmology sector will be fully evident tomorrow as we host the largest Ophthalmology Innovation Summit in its seven-year history. More than 900 clinicians, investors, and executives will descend upon the Planet Hollywood Hotel in Las Vegas to grab a glimpse of novel new treatments for ophthalmology disorders. Three dozen…

Celniker Gets Eleven Bio Ready For OIS and Conference Season

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 065″] Eleven Biotherapeutics last spring issued some disappointing news when its leading project, EBI-005, didn’t fare well in a Phase III trial for Dry Eye. However, the company’s AMP-Rx platform is chugging along and its EBI-005 is making progress against other conditions including allergic conjunctivitis. CEO and President Abbie C. Celniker,…

Ora’s Ousler Delves Deep Into Dry Eye

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 064″] Dry Eye remains one of the more dynamic sectors of ophthalmology with Shire’s recent news about its lead Lifitegrast product moving toward FDA approval. Ora knows Dry Eye better than most, and Vice President George Ousler helps fill in the blanks about Dry Eye’s future. Ora also published a paper…

Biogen’s High Hopes For Gene Therapy, Ophthalmology

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 062″] In July, Biogen signed a potential $1 billion-plus deal with Applied Genetic Technologies Corp. The deal, which included an equity investment, centered around AGTC’s leading gene therapy programs developing treatments for rare ophthalmic conditions X -Linked Retinoschisis (XLRS) and X-linked Retinitis Pigmentosa (XLRP). In this podcast, Josh Mandel-Brehm, Director, Business…

FDA Making the Rounds in Ophthalmology

Over the past week, news about the FDA has been flooding the inboxes of ophthalmology watchers. The most notable news came Shire plc. The regulatory agency requested that Shire conduct an additional clinical trial as part of a complete response letter for the company’s NDA for lifitegrast, a potential treatment for dry eye disease in…

Understanding Market Cycles: When Could Biotech UnBoom?

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 061″] David Nierengarten, Managing Director, Wedbush Securities, explains how public market cycles could hit biotech and ophthalmology companies. Podcast Guest David Nierengarten, PhD David Nierengarten is a senior biotechnology equity analyst with Wedbush Securities, mainly covering development-stage therapeutic companies. He began his career on the financial side of biotechnology at a…

Gene Therapies Move One Step Closer to Reality

Positive top-line results from a pivotal Phase III study may result in the first gene therapy to win U.S. regulatory approval, and sent shares of the developer skyrocketing. Earlier this week, Spark Therapeutics (Philadelphia) announced its lead candidate, SPK-RPE65, was able to improve functional vision in patients with a rare form of a genetic disorder…

Can Spark Phase III Results Ignite Gene Therapy?

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 060″] Jeffrey D. Marrazzo, Co-Founder and CEO of Spark Therapeutics, discusses the successful Phase III trial of its lead candidate, SPK-RPE65, was able to improve functional vision in patients with a rare form of a genetic disorder known as RPE65-mediated inherited retinal dystrophies. SPK-RPE65 is intended to treat rare blinding conditions…

Imprimis’ Baum On Disrupting Compound Pharmacies

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 056″] Imprimis Pharmaceuticals is disrupting the compound pharmaceutical industry, a segment of health care that’s undergoing significant regulatory upheaval. The company’s line of ophthalmology drugs could reduce or eliminate the need for post-surgical eye drops. Its approach is drawing support from many, including Dr. Richard Lindstrom, who serves on the company’s…

Opthea Exploring Different Approach To Treating Wet AMD

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 055″] Australia-based Opthea is moving forward with clinical trials in the US, testing its OPT-302 compound along and in combination with Lucentis as a potential treatment for Wet AMD. CEO Megan Baldwin explains the company’s approach up until now and its plans going forward. Podcast Guest Megan Baldwin Dr. Megan Baldwin…